University of California

Immuno-Oncology360º Announces 2024 Keynotes and Featured Speakers for the 10th Annual NYC Meeting

Retrieved on: 
Thursday, October 19, 2023

NEW YORK, Oct. 19, 2023 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 10th annual Immuno-Oncology 360º Summit (IO360°) taking place February 27-29, 2024, at New York Marriott Brooklyn Bridge, in Brooklyn, NY.

Key Points: 
  • The Conference Forum announced the IO360º Summit's 2024 keynotes and featured speakers for its 10th annual conference.
  • NEW YORK, Oct. 19, 2023 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 10th annual Immuno-Oncology 360º Summit (IO360°) taking place February 27-29, 2024, at New York Marriott Brooklyn Bridge, in Brooklyn, NY.
  • The IO360° 2024 keynotes include:
    Genentech's Ira Mellman, PhD, VP, Cancer Immunology, will speak on the roles of data mining and AI, and other clinical and translational data, in discovery and trial design.
  • "The IO360º conference presents the latest data impacting the IO landscape and for the 10th annual event, we are pleased to announce the extraordinary leadership advancing this space.

Paragon Legal Expands Career Connect Program Nationwide, Collaborating with Santa Clara University School of Law, William & Mary Law School, and Leading Industry Partners

Retrieved on: 
Thursday, October 19, 2023

Paragon is a legal services firm providing attorneys and legal professionals on an interim or on-demand basis to in-house legal departments.

Key Points: 
  • Paragon is a legal services firm providing attorneys and legal professionals on an interim or on-demand basis to in-house legal departments.
  • The Career Connect program is an innovative partnership between Paragon and leading companies to enhance talent and foster diversity in corporate legal departments, enabling recent law school graduates to get hands-on in-house legal experience directly out of law school.
  • "William & Mary (W&M) Law School is excited to partner with Paragon's Diversity, Equity & Inclusion (DE&I) Career Connect Program.
  • "We are thrilled to congratulate Ashim as he embarks on his career as a 2023 DE&I Career Connect Program Attorney."

Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023

Retrieved on: 
Thursday, October 5, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a virtual Investor and Analyst Day on Thursday, October 19, 2023 from 8:30 AM to 11:30 AM ET.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a virtual Investor and Analyst Day on Thursday, October 19, 2023 from 8:30 AM to 11:30 AM ET.
  • Interested parties must register online at https://cytokinetics-new-horizons-in-hypercontractility.open-exchange.net/ .
  • Registered attendees may access the virtual event platform by visiting the Investor & Media section of the Cytokinetics website at www.cytokinetics.com .
  • A link to the webcast replay will be archived on the Cytokinetics website until April 19, 2024.

Aviceda Announces AVD-104, a Novel Glycomimetic Nanoparticle, Demonstrates Continued Clinical Safety in the Treatment of Geographic Atrophy Secondary to Macular Degeneration

Retrieved on: 
Wednesday, October 11, 2023

The Phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-related macular degeneration (AMD).

Key Points: 
  • The Phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-related macular degeneration (AMD).
  • Notably, no drug-related ocular inflammation, retinal vasculitis, choroidal neovascularization, infection, or optic nerve abnormalities were observed in any eyes.
  • Treatment also reduced choroidal neovascular (CNV) lesion sizes comparable to aflibercept in a laser induced CNV mouse model.
  • “We are eager for the continuation of parts 1 and 2 of the US Phase 2/3 SIGLEC clinical trial for patients with AMD-related geographic atrophy.

Karius Test® Improves the Diagnosis and Management of Pneumonia in Patients Undergoing Treatment for Blood Cancer

Retrieved on: 
Tuesday, October 10, 2023

“Often clinicians must weigh the risks of invasive procedures in medically fragile patients with an anticipated low diagnostic yield.

Key Points: 
  • “Often clinicians must weigh the risks of invasive procedures in medically fragile patients with an anticipated low diagnostic yield.
  • Identifying the specific cause of pneumonia in patients with blood cancers who are often severely immunocompromised is difficult and critically important to successful treatment.
  • “This well-designed clinical trial conducted at leading academic centers shows that the Karius Test is highly valuable in immunocompromised patients with suspected infection,” said Dr. Ned Sharpless, former Director, National Cancer Institute, and newest Karius board member.
  • “These patients have much to gain through an improved etiologic diagnosis, and the better and more directed treatment of these infections that make this possible,” said Brad Perkins, Chief Medical Officer at Karius.

SPIE Photonics West 2024 Opens for Registration

Retrieved on: 
Thursday, October 5, 2023

Registration has opened for SPIE Photonics West 2024 , which will run from 27 January to 1 February at the Moscone Center in San Francisco.

Key Points: 
  • Registration has opened for SPIE Photonics West 2024 , which will run from 27 January to 1 February at the Moscone Center in San Francisco.
  • View the full release here: https://www.businesswire.com/news/home/20231005492002/en/
    Attendees at SPIE Photonics West 2023 (Photo: Business Wire)
    SPIE Photonics West has four major application areas emphasizing the latest technologies and discoveries that utilize optics and photonics.
  • All three exhibitions and the industry program are free to attend with a SPIE Photonics West registration.
  • “Photonics West 2024 promises to be an engaging and thought-provoking week of networking and learning opportunities,” said SPIE Senior Director of Technical Programs Marilyn Gorsuch.

KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS

Retrieved on: 
Thursday, October 5, 2023

SYDNEY, Oct. 5, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update regarding upcoming data presentations at two international scientific meetings, European Society for Medical Oncology (ESMO) Congress 2023 and Society for Neuro-Oncology (SNO) Annual Meeting.

Key Points: 
  • SYDNEY, Oct. 5, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update regarding upcoming data presentations at two international scientific meetings, European Society for Medical Oncology (ESMO) Congress 2023 and Society for Neuro-Oncology (SNO) Annual Meeting.
  • The presentations will highlight data for both investigational clinical drugs, EVT801 and Paxalisib.
  • Title: Phase 1 study of paxalisib and radiotherapy for CNS disease harboring PI3K pathway mutations: pilot analysis of circulating tumor DNA for patient eligibility confirmation and post treatment response
    Presenter: Brandon S. Imber (Memorial Sloan Kettering Cancer Center, New York)
    Title: PNOC022: A combination therapy trial using an adaptive platform design for patients with Diffuse Midline Gliomas (DMGs) at initial diagnosis, post-radiation therapy and at time of Progression
    Presenter: Sabine Mueller (University of California, San Francisco)

Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Retrieved on: 
Monday, October 2, 2023

“Today’s acceptance of the BLA by the FDA marks a significant milestone for Rocket towards our goal of delivering a one-time gene therapy to patients facing the devastating effects of severe LAD-I.

Key Points: 
  • “Today’s acceptance of the BLA by the FDA marks a significant milestone for Rocket towards our goal of delivering a one-time gene therapy to patients facing the devastating effects of severe LAD-I.
  • All primary and secondary endpoints were met, and RP-L201 was very well tolerated in all patients with no treatment related SAEs.
  • “As the Principal Investigator in the U.S., I oversaw treatment of six of the nine LAD-I patients in this trial.
  • All of these children have been in good health with no significant LAD-I-related infections or inflammatory skin lesions since treatment.

KB Home First and Only Homebuilder Named to Fortune’s 2023 Change the World List

Retrieved on: 
Friday, September 29, 2023

KB Home (NYSE: KBH), one of the largest and most recognized homebuilders in the U.S., has been acknowledged for its sustainability leadership by Fortune, which named the company the first and only builder on its 2023 Change the World list.

Key Points: 
  • KB Home (NYSE: KBH), one of the largest and most recognized homebuilders in the U.S., has been acknowledged for its sustainability leadership by Fortune, which named the company the first and only builder on its 2023 Change the World list.
  • This prestigious list highlights 50 select companies that have created a positive impact on society through activities such as sustainability that are part of their core business strategies.
  • View the full release here: https://www.businesswire.com/news/home/20230929960523/en/
    KB Home first and only homebuilder named to Fortune’s 2023 Change the World List (Photo: Business Wire)
    KB Home was honored for building the first residential microgrid communities of all-electric, solar- and battery-powered homes in California.
  • “We’re honored to be named to Fortune’s Change the World list, the first and only homebuilder to make this distinguished list.

Sonoma Biotherapeutics Appoints Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer

Retrieved on: 
Friday, September 29, 2023

Sonoma Bio Co-founder and Chief Scientific Officer, Fred Ramsdell, Ph.D., will retire and remain a member of the Company’s Scientific Advisory Board.

Key Points: 
  • Sonoma Bio Co-founder and Chief Scientific Officer, Fred Ramsdell, Ph.D., will retire and remain a member of the Company’s Scientific Advisory Board.
  • “Joe and Mark have established track records of driving scientific and clinical strategy to advance novel therapies for patients living with devastating diseases,” said Jeff Bluestone, Ph.D., Co-founder and Chief Executive Officer of Sonoma Biotherapeutics.
  • I’d also like to extend my gratitude to my long-time collaborator and colleague, Fred Ramsdell, for his immense contributions to Sonoma Bio.
  • “Sonoma Bio is reimagining the chronic treatment paradigm that patients with autoimmune and inflammatory diseases face today,” said Dr. Eisner.